The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
Open accessAbstract
BACKGROUND: Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing apoptosis. APR-246 has been tested as monotherapy in a Phase I/IIa clinical study in hematological malignancies and prostate cancer with promising results, and a Phase Ib/II study in combination with platinum-based therapy in ovarian cancer is ongoing. In the present study, we investigated the anticancer effects of APR-246 in combination with conventional chemotherapy in primary cancer cells isolated from ascitic fluid from 10 ovarian, fallopian tube, or peritoneal cancer patients, 8 of which had HGS cancer. METHODS: Cell viability was assessed with fluorometric microculture cytotoxicity assay (FMCA) and Combination Index was calculated using the Additive model. p53 status was determined by Sanger sequencing and single strand conformation analysis, and p53 protein expression by western blotting. RESULTS: We observed strong synergy with APR-246 and cisplatin in all tumor samples carrying a TP53 missense mutation, while synergistic or additive effects were found in cells with wild type or TP53 nonsense mutations. Strong synergy was also observed with carboplatin or doxorubicin. Moreover, APR-246 sensitized TP53 mutant primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of cisplatin decreased 3.6 fold from 6.5 to 1.8 μM in the presence of clinically relevant concentration of APR-246. CONCLUSION: These results suggest that combination treatment with APR-246 and DNA-damaging drugs could significantly improve the treatment of patients with TP53 mutant HGS cancer, and thus provide strong support for the ongoing clinical study with APR-246 in combination with carboplatin and pegylated liposomal doxorubicin in patients with recurrent HGS cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (14)(15)(16)(17)(18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (15,19–22). Whereas HEY-CTLshRNA cells were practically insensitive to APR-246, HEY-CIP2AshRNA cells showed a >50% reduction in cell viability (Fig. 1A).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2008) · Oncogene · doi:10.1038/onc.2008.249 · Cited by 57
Self-citationRetractedErratum: PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2016) · Oncogene · doi:10.1038/onc.2016.210 · Cited by 55 · cited 2×
“This induces activation of caspase-2 and expression of p53-target genes, including, PUMA, NOXA, and BAX, leading to mitochondrial apoptosis [9, 10, 30].”
BackgroundSelf-citationRetractedThe resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717 · cited 2×
“Platinum-based drugs have for decades been used for effective treatment of many solid tumors, including ovarian cancer [25, 26].”
BackgroundOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434 · cited 1×
“The TP53 gene status (exons 2–11) was analyzed by PCR amplification and sequencing, followed by single-strand conformation analysis (SSCA) according to the original protocol [22], and samples displaying gel mobility shifts were sequenced to confirm the nucleotide change.”
MethodCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“Platinum-based drugs have for decades been used for effective treatment of many solid tumors, including ovarian cancer [25, 26].”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Mutations in TP53 are identified in about 50 % of all tumors and are associated with increased resistance to chemotherapy and reduced survival in many tumor types [7, 8].”
BackgroundDNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829 · cited 1×
“The main mechanisms of action of doxorubicin are inhibition of DNA and RNA synthesis by intercalation between base pairs of the DNA/RNA strands, and interference with the topoisomerase II enzyme, leading to double-strand breaks [35].”
BackgroundOvarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672 · cited 2×
“Cancer cells in ascites mirror most of the molecular characteristics of cells in the primary tumor and at metastatic sites [32].”
BackgroundMolecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564 · cited 1×
“drug-induced increase in intracellular glutathione (GSH) levels leading to enhanced efflux of platinum compounds, reduced drug uptake, increased drug inactivation, as well as inactivation of the tumor suppressor protein p53 [26–29].”
BackgroundEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418 · cited 1×
“Indeed, pronounced differences between some of the most commonly used HGS ovarian cancer cell line models and the majority of HGS ovarian cancer samples have been revealed [14, 15].”
Background
Cited by
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Richardson, D. L., Eskander, R. N., & O’Malley, D. M. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0197 · Cited by 226
Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132
Chen, P., Liu, X.-Q., Lin, X., Gao, L., Zhang, S., & Huang, X. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.001 · Cited by 134
“The evaluation of synergistic effects by GLS inhibitor and cisplatin was conducted using the algorithm described by Fransson et al.(25) Synergy is determined by calculating a CI.”
Method
Metadata
- Authors
- Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N.
- Affiliations
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Mohell, Nina
- ORCID
- Wiman, Klas G.
- Venue
- Journal of Ovarian Research
- Published
- 2016-05-14
- Volume
- 9
- Issue
- 1
- Pages
- 27-27
- ISSN
- 1757-2215 (ISSN-L)
- PMC
- PMC4868029
- OpenAlex
- W2355389606
- Cited by
- 65
- References
- 41
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 9 · 2021: 12 · 2020: 4 · 2019: 11 · 2018: 7 · 2017: 7 · 2016: 1
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Ovarian Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- the Swedish Cancer Society (130260, 140616)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- APR-246, TP53 mutation, high-grade serous ovarian cancer, cisplatin, carboplatin, doxorubicin, DNA-damaging chemotherapy, drug synergy, p53 reactivation, platinum resistance, primary tumor cells, combination therapy
- MeSH terms
- Antineoplastic Agents, Cell Survival, Cisplatin, DNA Damage, Drug Synergism, Female, Humans, Mutation, Neoplasm Staging, Ovarian Neoplasms, Quinuclidines, Tumor Suppressor Protein p53, Cystadenocarcinoma, Serous, Drug Resistance, Neoplasm, Inhibitory Concentration 50, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. https://app.cochat.ai/papers/10.1186/s13048-016-0239-6
- The paper
- Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016). Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. Journal of Ovarian Research. https://doi.org/10.1186/s13048-016-0239-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.